Skip to content
Research Article Open access CC BY 4.0

Impact of Hepatitis C Virus (HCV) on CD4+ T-Lymphocyte Count < 200 cells/µL among HIV-Positive Adults: A Longitudinal Evaluation

Prosanta K. Mondal, Stephanie Konrad, Michael Schwandt, Stuart Skinner, Hyun Ja Lim

Journal of Advances in Medicine and Medical Research · pp. 1–8 · Published 17 Apr 2015

10.9734/BJMMR/2015/17517

Abstract

Aims: Previous research on whether Hepatitis C Virus (HCV)/HIV coinfection alters the natural history of HIV disease progression shows conflicting findings. The aim of this study is to investigate whether HCV/HIV coinfection has an adverse effect on the outcome of a CD4+ count &lt; 200 cells/µL in HIV-positive adults. Study Design: A retrospective longitudinal study. Place and Duration of Study: Royal University Hospital and West Side Community Clinic in Saskatoon, Canada. Individuals were diagnosed with HIV between January 1, 2005 and September 1, 2011. Methodology: Data were collected using medical charts. CD4+ count was dichotomized into a binary variable (1 for CD4+ count &lt; 200; 0 for ≥ 200). Independent t-tests or Wilcoxon test, and Chi-square tests were used to compare quantitative and qualitative variables between groups, respectively. The risk factors for CD4+ count &lt; 200 were determined using Generalized Estimating Equations (GEE) marginal logistic regression model. Analysis was done by SAS 9.4 and P&lt;0.05 was considered as statistically significant. Results: Among 369 patients, 48.5% were female, 72.1% were Aboriginals, 82.4% were HCV/HIV-coinfected and 77.4% had history of Injection Drug Use (IDU) at diagnosis. The mean age at diagnosis was 35.5 years. In univariate GEE logistic regression model, patients with coinfection of HCV/HIV, Aboriginals ethnicity, ever use of Antiretroviral Therapy (ART), social assistance, older age, and higher viral load at baseline were significantly more likely to have CD4+ count &lt; 200. In multivariate model, HCV/HIV coinfection, age, and ART were associated with CD4+ count &lt; 200. Patients with HCV/HIV coinfection, older age, and ever use of ART had significantly higher odds of having CD4+ count &lt; 200 (adjusted odds ratios 2.21, 1.48, and 2.70 respectively). Conclusions: HCV/HIV-coinfected patients were significantly more likely to have CD4+ count &lt; 200. Results support earlier treatment of HCV and HIV as well as increased monitoring for coinfected individuals.

HIV AIDS CD4 count ART HCV IDU GEE Aboriginals

References (23)

  1. 1 Longitudinal Data Analysis Using Generalized Linear Models [DOI]
  2. 2 Akaike's Information Criterion in Generalized Estimating Equations [DOI]
  3. 3 The global burden of hepatitis C [DOI]
  4. 4 Epidemiology of viral hepatitis and HIV co-infection [DOI]
  5. 5 Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study [DOI]
  6. 6 Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals [DOI]
  7. 7 Hepatitis C and Progression of HIV Disease [DOI]
  8. 8 Influence of Hepatitis C Virus Infection on HIV‐1 Disease Progression and Response to Highly Active Antiretroviral Therapy [DOI]
  9. 9 Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens.
  10. 10 Meta‐Analysis: Increased Mortality Associated with Hepatitis C in HIV‐Infected Persons Is Unrelated to HIV Disease Progression [DOI]
  11. 11 Treatment to Prevent Transmission of HIV‐1 [DOI]
  12. 12 Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort [DOI]
  13. 13 Impact of hepatitis C viral replication on CD4+ T-lymphocyte progression in HIV–HCV coinfection before and after antiretroviral therapy [DOI]
  14. 14 Hepatitis C virus co‐infection is a negative prognostic factor for clinical evolution in human immunodeficiency virus‐positive patients [DOI]
  15. 15 Hepatitis C in HIV‐infected individuals: cure and control, right now [DOI]
  16. 16 Hepatitis C Virus Infection in HIV Type 1--Infected Individuals Does Not Accelerate a Decrease in the CD4+ Cell Count but Does Increase the Likelihood of AIDS-Defining Events [DOI]
  17. 17 The effect of hepatitis C on progression to AIDS before and after highly active antiretroviral therapy [DOI]
  18. 18 Joint modeling of longitudinal and event time data: application to HIV study [DOI]
  19. 19 Impact of Hepatitis C Virus on HIV Response to Antiretroviral Therapy in Nigeria [DOI]
  20. 20 HIV Disease Progression to CD4 Count <200 Cells/μL and Death in Saskatoon, Saskatchewan [DOI]
  21. 21 Impact of Chronic Hepatitis C on HIV-1 Disease Progression [DOI]
  22. 22 Virological effectiveness and CD4+ T-cell increase over early and late courses in HIV infected patients on antiretroviral therapy: focus on HCV and anchor class received [DOI]
  23. 23 CD4 T-Lymphocyte Recovery in Individuals With Advanced HIV-1 Infection Receiving Potent Antiretroviral Therapy for 4 Years

Cited by 0

No indexed citations yet.

Related research

Article metrics

Real usage data collected on this platform.

44

Page views

0

PDF downloads

20

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.